This case study outlines a randomised, multi-centre, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as a monotherapy in newly diagnosed partial epilepsy.

A large pharmaceutical client selected PRA to conduct two Phase III epilepsy studies in India, Eastern and Western Europe, and Australia.

PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.